{
  "success": true,
  "sourceFile": "input/Alexion_NCT04573309_Wilsons_SAP.pdf",
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33
  ],
  "modelUsed": "gpt-5.2",
  "sapData": {
    "analysisPopulations": [
      {
        "id": "pop_1",
        "name": "Screened Set",
        "text": "The Screened Set includes all subjects who signed an informed consent form.",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "populationDescription": "The Screened Set includes all subjects who signed an informed consent form.",
        "criteria": "Signed informed consent form"
      },
      {
        "id": "pop_2",
        "name": "Enrolled Set",
        "text": "The Enrolled Set includes all subjects who are enrolled into the study.",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "populationDescription": "The Enrolled Set includes all subjects who are enrolled into the study.",
        "criteria": "Enrolled into the study"
      },
      {
        "id": "pop_3",
        "name": "Full Analysis Set",
        "text": "The Full Analysis Set includes all enrolled subjects who received at least 1 dose of ALXN1840.",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "FA",
        "populationDescription": "The Full Analysis Set includes all enrolled subjects who received at least 1 dose of ALXN1840.",
        "criteria": "Enrolled AND received ≥1 dose of ALXN1840"
      },
      {
        "id": "pop_4",
        "name": "Per Protocol Set",
        "text": "The Per Protocol Set includes all subjects in the Full Analysis Set who did not have any major protocol deviations that could impact the primary endpoint.",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "PP",
        "populationDescription": "The Per Protocol Set includes all subjects in the Full Analysis Set who did not have any major protocol deviations that could impact the primary endpoint.",
        "criteria": "In Full Analysis Set AND no major protocol deviations impacting the primary endpoint"
      },
      {
        "id": "pop_5",
        "name": "Safety Set",
        "text": "The Safety Set includes all enrolled subjects who received at least 1 dose of ALXN1840.",
        "populationType": "Safety",
        "instanceType": "AnalysisPopulation",
        "populationDescription": "The Safety Set includes all enrolled subjects who received at least 1 dose of ALXN1840.",
        "criteria": "Enrolled AND received ≥1 dose of ALXN1840"
      },
      {
        "id": "pop_6",
        "name": "Pharmacokinetic Analysis Set",
        "text": "The Pharmacokinetic Analysis Set includes all subjects in the Safety Set who have at least 1 post-dose pharmacokinetic assessment.",
        "populationType": "PK/PD",
        "instanceType": "AnalysisPopulation",
        "populationDescription": "The Pharmacokinetic Analysis Set includes all subjects in the Safety Set who have at least 1 post-dose pharmacokinetic assessment.",
        "criteria": "In Safety Set AND has ≥1 post-dose PK assessment"
      },
      {
        "id": "pop_7",
        "name": "Pharmacodynamic Analysis Set",
        "text": "The Pharmacodynamic Analysis Set includes all subjects in the Safety Set who have at least 1 post-dose pharmacodynamic assessment.",
        "populationType": "PK/PD",
        "instanceType": "AnalysisPopulation",
        "populationDescription": "The Pharmacodynamic Analysis Set includes all subjects in the Safety Set who have at least 1 post-dose pharmacodynamic assessment.",
        "criteria": "In Safety Set AND has ≥1 post-dose PD assessment"
      }
    ],
    "characteristics": [],
    "summary": {
      "populationCount": 7,
      "characteristicCount": 0
    }
  }
}